Profile
Sector:
HealthcareIndustry:
Drug Manufacturers - GeneralCountry:
IrelandIPO:
01 April 1993Website:
http://www.amarincorp.comNext earnings report:
02 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | 0 min agoDividend
Analysts recommendations
Institutional Ownership
AMRN Latest News
LA BOUTIQUE, the leading Thai fashion designer brand celebrated for its neo-romantic and new vintage aesthetic, is thrilled to announce the grand opening of its latest flagship store at Gaysorn Amarin LA BOUTIQUE, the leading Thai fashion designer brand celebrated for its neo-romantic and new vintage aesthetic, is thrilled to announce the grand opening of its latest flagship store at Gaysorn Amarin
-- Board Appoints Aaron Berg as President & CEO -- -- Patrick Holt to Step Down as President & CEO to Pursue Other Opportunities --
Here is a comparison of the performance of Amarin (AMRN) and ANI Pharmaceuticals (ANIP) within their sector for the year to date.
Amarin (AMRN) reports stronger-than-anticipated first-quarter 2024 earnings, but sales of Vascepa in the US are still impacted by generic rivals.
Amarin (AMRN) secures a new patent for Vazkepa in Europe, which extends its exclusivity for eight more years. It achieves success in defending another patent on the drug against third parties.
Amarin's Vazkepa notched a crucial win with a European regulator. The medication earned an extension to its patent exclusivity on that market.
Amarin's (AMRN) fourth-quarter 2023 earnings and revenues beat estimates. Vascepa's sales in the United States decline year over year.
Amarin Corporation plc (AMRN) Q4 2023 Earnings Call Transcript
Let us look at some drug/biotech stocks, MRNA, BMRN, AMRN, NTLA and BEAM, which are poised to beat on fourth-quarter earnings.
Sarissa Capital is successfully turning around Amarin, giving it new life and potential for success. Amarin's REDUCE-IT trial proved the cardiovascular benefits of its purified EPA product, Vascepa, leading to its potential for greatness. The implementation of strategic proposals, a new CEO with relevant expertise, and higher than expected Q4 earnings are positive signs for Amarin's future.
- 1(current)
What type of business is Amarin?
Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, Germany, Canada, Lebanon, and the United Arab Emirates. Its lead product is VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally to wholesalers and specialty pharmacy providers. It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, and eicosapentaenoic acid. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.
What sector is Amarin in?
Amarin is in the Healthcare sector
What industry is Amarin in?
Amarin is in the Drug Manufacturers - General industry
What country is Amarin from?
Amarin is headquartered in Ireland
When did Amarin go public?
Amarin initial public offering (IPO) was on 01 April 1993
What is Amarin website?
https://www.amarincorp.com
Is Amarin in the S&P 500?
No, Amarin is not included in the S&P 500 index
Is Amarin in the NASDAQ 100?
No, Amarin is not included in the NASDAQ 100 index
Is Amarin in the Dow Jones?
No, Amarin is not included in the Dow Jones index
When does Amarin report earnings?
The next expected earnings date for Amarin is 02 August 2024